SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Rejko Krüger, Rüdiger Hilker, Christian Winkler, Michael Lorrain, Matthias Hahne, Christoph Redecker, Paul Lingor, Wolfgang H. Jost, Advanced stages of PD: interventional therapies and related patient-centered care, Journal of Neural Transmission, 2016, 123, 1, 31

    CrossRef

  2. 2
    M.J. Lelos, R.J. Morgan, C.M. Kelly, E.M. Torres, A.E. Rosser, S.B. Dunnett, Amelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's disease, Experimental Neurology, 2016, 278, 54

    CrossRef

  3. 3
    Haidar Salimi Dafsari, Prashanth Reddy, Christiane Herchenbach, Stefanie Wawro, Jan Niklas Petry-Schmelzer, Veerle Visser-Vandewalle, Alexandra Rizos, Monty Silverdale, Keyoumars Ashkan, Michael Samuel, Julian Evans, Carlo A. Huber, Gereon R. Fink, Angelo Antonini, K. Ray Chaudhuri, Pablo Martinez-Martin, Lars Timmermann, Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease, Brain Stimulation, 2016, 9, 1, 78

    CrossRef

  4. 4
    J. Timpka, T. Fox, K. Fox, H. Honig, P. Odin, P. Martinez-Martin, A. Antonini, K. Ray Chaudhuri, Improvement of dyskinesias with l-dopa infusion in advanced Parkinson's disease, Acta Neurologica Scandinavica, 2016, 133, 3
  5. 5
    Florence C.F. Chang, Vu Kwan, David van der Poorten, Neil Mahant, Nigel Wolfe, Ainhi D. Ha, Jane M. Griffith, David Tsui, Samuel D. Kim, Victor S.C. Fung, Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s disease, Journal of Clinical Neuroscience, 2016, 25, 41

    CrossRef

  6. 6
    Florence C.F. Chang, David S. Tsui, Neil Mahant, Nigel Wolfe, Samuel D. Kim, Ainhi D. Ha, Melissa Drury, Jane M. Griffith, Victor S.C. Fung, 24 h Levodopa–carbidopa intestinal gel may reduce falls and “unresponsive” freezing of gait in Parkinson's disease, Parkinsonism & Related Disorders, 2015, 21, 3, 317

    CrossRef

  7. 7
    P. Odin, K. Ray Chaudhuri, J.T. Slevin, J. Volkmann, E. Dietrichs, P. Martinez-Martin, J.K. Krauss, T. Henriksen, R. Katzenschlager, A. Antonini, O. Rascol, W. Poewe, Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program, Parkinsonism & Related Disorders, 2015, 21, 10, 1133

    CrossRef

  8. 8
    Gennaro Pagano, Echo E Tan, Janelle M. Haider, Alyssa Bautista, Michele Tagliati, Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease, Parkinsonism & Related Disorders, 2015, 21, 2, 120

    CrossRef

  9. 9
    Mallory L. Hacker, James Tonascia, Maxim Turchan, Amanda Currie, Lauren Heusinkveld, Peter E. Konrad, Thomas L. Davis, Joseph S. Neimat, Fenna T. Phibbs, Peter Hedera, Lily Wang, Yaping Shi, David M. Shade, Alice L. Sternberg, Lea T. Drye, David Charles, Deep brain stimulation may reduce the relative risk of clinically important worsening in early stage Parkinson's disease, Parkinsonism & Related Disorders, 2015, 21, 10, 1177

    CrossRef

  10. 10
    Alexander Alamri, Ismail Ughratdar, Michael Samuel, Keyoumars Ashkan, Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 2003–2013: Where are we another 10 years on?, British Journal of Neurosurgery, 2015, 29, 3, 319

    CrossRef

  11. 11
    F. Bellante, S. Dethy, D. Zegers de Beyl, Depression, anxiety and non-motor symptoms on initiation of intrajejunal levodopa/carbidopa therapy, Acta Neurologica Belgica, 2015,

    CrossRef

  12. 12
    Pantelis Stathis, Spiridon Konitsiotis, Angelo Antonini, Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias, Expert Review of Neurotherapeutics, 2015, 15, 2, 207

    CrossRef

  13. 13
    Pablo Martinez-Martin, Carmen Rodriguez-Blazquez, Maria João Forjaz, Monica M. Kurtis, Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson’s Disease, CNS Drugs, 2015, 29, 5, 397

    CrossRef

  14. 14
    Hubert H. Fernandez, David G. Standaert, Robert A. Hauser, Anthony E. Lang, Victor S.C. Fung, Fabian Klostermann, Mark F. Lew, Per Odin, Malcolm Steiger, Eduard Z. Yakupov, Sylvain Chouinard, Oksana Suchowersky, Jordan Dubow, Coleen M. Hall, Krai Chatamra, Weining Z. Robieson, Janet A. Benesh, Alberto J. Espay, Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results, Movement Disorders, 2015, 30, 4
  15. 15
    Oluwadamilola O Ojo, Hubert H Fernandez, Levodopa/carbidopa intestinal gel: an effective formulation for the management of advanced Parkinson's disease, Future Neurology, 2015, 10, 3, 191

    CrossRef

  16. 16
    Maríateresa Buongiorno, Francesca Antonelli, Ana Cámara, Victor Puente, Oriol de Fabregues-Nebot, Jorge Hernandez-Vara, Matilde Calopa, Berta Pascual-Sedano, Antonia Campolongo, Francesc Valldeoriola, Eduardo Tolosa, Jaime Kulisevsky, Maria Jose Martí, Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry, Parkinsonism & Related Disorders, 2015, 21, 8, 871

    CrossRef

  17. 17
    W.-H. Chiu, C. Depboylu, G. Hermanns, L. Maurer, A. Windolph, W.H. Oertel, V. Ries, G.U. Höglinger, Long-term treatment with l-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease, Neuropharmacology, 2015, 95, 367

    CrossRef

  18. 18
    Ashish Kumar Kakkar, Neha Dahiya, Management of Parkinson׳s disease: Current and future pharmacotherapy, European Journal of Pharmacology, 2015, 750, 74

    CrossRef

  19. 19
    Werner Poewe, Angelo Antonini, Novel formulations and modes of delivery of levodopa, Movement Disorders, 2015, 30, 1
  20. 20
    Lisa Klingelhoefer, Heinz Reichmann, Amos D. Korczyn, Heinz Reichmann, K. Ray Chaudhuri, Parkinson’s Disease and Gastrointestinal Non Motor Symptoms: Diagnostic and Therapeutic Options – A Practise Guide, Journal of Parkinson's Disease, 2015, 5, 3, 647

    CrossRef

  21. 21
    Matthieu F. Bastide, Wassilios G. Meissner, Barbara Picconi, Stefania Fasano, Pierre-Olivier Fernagut, Michael Feyder, Veronica Francardo, Cristina Alcacer, Yunmin Ding, Riccardo Brambilla, Gilberto Fisone, A. Jon Stoessl, Mathieu Bourdenx, Michel Engeln, Sylvia Navailles, Philippe De Deurwaerdère, Wai Kin D. Ko, Nicola Simola, Micaela Morelli, Laurent Groc, Maria-Cruz Rodriguez, Eugenia V. Gurevich, Maryka Quik, Michele Morari, Manuela Mellone, Fabrizio Gardoni, Elisabetta Tronci, Dominique Guehl, François Tison, Alan R. Crossman, Un Jung Kang, Kathy Steece-Collier, Susan Fox, Manolo Carta, M. Angela Cenci, Erwan Bézard, Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease, Progress in Neurobiology, 2015, 132, 96

    CrossRef

  22. 22
    Thien Thien Lim, Benzi M. Kluger, Ramon L. Rodriguez, Irene A. Malaty, Rafael Palacio, Oluwadamilola O. Ojo, Shnehal Patel, Yogesh Gujrati, Benjamin Nutter, Camille Swartz, Carol Hennessy, Hubert H. Fernandez, Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease, Movement Disorders, 2015, 30, 13
  23. 23
    O. Băjenaru, A. Ene, B. O. Popescu, J. A. Szász, M. Sabău, D. F. Mureşan, L. Perju-Dumbrava, C. D. Popescu, A. Constantinescu, I. Buraga, M. Simu, The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience, Journal of Neural Transmission, 2015,

    CrossRef

  24. 24
    Paolina Pantcheva, Stephanny Reyes, Jaclyn Hoover, Sussannah Kaelber, Cesar V Borlongan, Treating non-motor symptoms of Parkinson’s disease with transplantation of stem cells, Expert Review of Neurotherapeutics, 2015, 15, 10, 1231

    CrossRef

  25. 25
    Christiana Ossig, Heinz Reichmann, Treatment Strategies in Early and Advanced Parkinson Disease, Neurologic Clinics, 2015, 33, 1, 19

    CrossRef

  26. 26
    Mariachiara Sensi, F. Preda, L. Trevisani, E. Contini, D. Gragnaniello, J. G. Capone, E. Sette, N. Golfre-Andreasi, V. Tugnoli, M. R. Tola, R. Quatrale, Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients, Journal of Neural Transmission, 2014, 121, 6, 633

    CrossRef

  27. 27
    M. Zibetti, A. Merola, C. A. Artusi, L. Rizzi, S. Angrisano, D. Reggio, C. Angelis, M. Rizzone, L. Lopiano, Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience, European Journal of Neurology, 2014, 21, 2
  28. 28
    María Ascensión Zea-Sevilla, Pablo Martínez-Martín, Rating scales and questionnaires for assessment of sleep disorders in Parkinson’s disease: what they inform about?, Journal of Neural Transmission, 2014, 121, S1, 33

    CrossRef

  29. 29
    Fabrizio Stocchi, Paola Stirpe, The relevance of dopaminergic level in nocturnal disability in Parkinson’s disease: implications of continuous dopaminergic stimulation at night to treat the symptoms, Journal of Neural Transmission, 2014, 121, S1, 79

    CrossRef

  30. 30
    Karoline Wenzel, Carl Nikolaus Homann, Giovanni Fabbrini, Carlo Colosimo, The role of subcutaneous infusion of apomorphine in Parkinson’s disease, Expert Review of Neurotherapeutics, 2014, 14, 7, 833

    CrossRef

  31. 31
    Philip C. Buttery, Roger A. Barker, Treating Parkinson's disease in the 21st century: Can stem cell transplantation compete?, Journal of Comparative Neurology, 2014, 522, 12
  32. 32
    Adolfo Ramirez-Zamora, Eric Molho, Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions, Expert Review of Neurotherapeutics, 2014, 14, 1, 93

    CrossRef

  33. 33
    Wolfgang H Jost, Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration, Expert Opinion on Drug Safety, 2014, 13, 4, 447

    CrossRef

  34. 34
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Advanced Parkinson's disease: Clinical characteristics and treatment. Part II, Neurología (English Edition), 2013, 28, 9, 558

    CrossRef

  35. 35
    Qing Lv, Baorong Zhang, Application of the concept of continuous dopaminergic stimulation for the management of Parkinson’s disease, Neuroscience Bulletin, 2013, 29, 5, 661

    CrossRef

  36. 36
    C. Moreau, A. Annic, D. Devos, L. Defebvre, Comment gérer un traitement par Duodopa® dans la maladie de Parkinson évoluée ?, Pratique Neurologique - FMC, 2013, 4, 1, 22

    CrossRef

  37. 37
    Brenton A Wright, Cheryl H Waters, Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease, Expert Review of Neurotherapeutics, 2013, 13, 6, 719

    CrossRef

  38. 38
    A. Antonini, P. Odin, L. opiano, V. Tomantschger, C. Pacchetti, B. Pickut, U. E. Gasser, D. Calandrella, F. Mancini, M. Zibetti, B. Minafra, I. Bertaina, P. De Deyn, C. Cras, E. Wolf, S. Spielberger, W. Poewe, Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care, Journal of Neural Transmission, 2013, 120, 11, 1553

    CrossRef

  39. 39
    Theresa A Zesiewicz, Pablo Martinez-Martin, Effects of rotigotine transdermal system on non-motor symptoms in Parkinson’s disease: an overview, Expert Review of Neurotherapeutics, 2013, 13, 12, 1329

    CrossRef

  40. 40
    J. Kulisevsky, M.R. Luquin, J.M. Arbelo, J.A. Burguera, F. Carrillo, A. Castro, J. Chacón, P.J. García-Ruiz, E. Lezcano, P. Mir, J.C. Martinez-Castrillo, I. Martínez-Torres, V. Puente, Á. Sesar, F. Valldeoriola-Serra, R. Yañez, Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II, Neurología, 2013, 28, 9, 558

    CrossRef

  41. 41
    Marina Picillo, Marianna Amboni, Roberto Erro, Katia Longo, Carmine Vitale, Marcello Moccia, Angela Pierro, Gabriella Santangelo, Anna Rosa, Giuseppe Michele, Lucio Santoro, Giuseppe Orefice, Paolo Barone, Maria Teresa Pellecchia, Gender differences in non-motor symptoms in early, drug naïve Parkinson’s disease, Journal of Neurology, 2013, 260, 11, 2849

    CrossRef

  42. 42
    P. F. Worth, How to treat Parkinson's disease in 2013, Clinical Medicine, 2013, 13, 1, 93

    CrossRef

  43. 43
    T. Foltynie, C. Magee, C. James, G. J. M. Webster, A. J. Lees, P. Limousin, Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series, Parkinson's Disease, 2013, 2013, 1

    CrossRef

  44. 44
    Diego Santos-García, Raúl de la Fuente-Fernández, Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease, Journal of the Neurological Sciences, 2013, 332, 1-2, 136

    CrossRef

  45. 45
    Barbara Anne Pickut, Chris van der Linden, Sophie Dethy, Hilde Van De Maele, Diederik Zegers de Beyl, Intestinal levodopa infusion: the Belgian experience, Neurological Sciences, 2013,

    CrossRef

  46. 46
    Manuela Pilleri, Konstantinos Koutsikos, Angelo Antonini, Is there room for new non-dopaminergic treatments in Parkinson’s disease?, Journal of Neural Transmission, 2013, 120, 2, 349

    CrossRef

  47. 47
    Maurizio Zibetti, Aristide Merola, Valeria Ricchi, Alice Marchisio, Carlo Alberto Artusi, Laura Rizzi, Elisa Montanaro, Dario Reggio, Claudio Angelis, Mario Rizzone, Leonardo Lopiano, Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study, Journal of Neurology, 2013, 260, 1, 105

    CrossRef

  48. 48
    K. Ray Chaudhuri, Alexandra Rizos, Kapil D. Sethi, Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?, Journal of Neural Transmission, 2013, 120, 9, 1305

    CrossRef

  49. 49
    Dag Nyholm, Per Odin, Anders Johansson, Krai Chatamra, Charles Locke, Sandeep Dutta, Ahmed A. Othman, Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients, The AAPS Journal, 2013, 15, 2, 316

    CrossRef

  50. 50
    K. Ray Chaudhuri, Pablo Martinez-Martin, Angelo Antonini, Richard G. Brown, Joseph H. Friedman, Marco Onofrj, Erwin Surmann, Liesbet Ghys, Claudia Trenkwalder, Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER, Parkinsonism & Related Disorders, 2013, 19, 7, 660

    CrossRef

  51. 51
    Jens Volkmann, Alberto Albanese, Angelo Antonini, K. Ray Chaudhuri, Carl E. Clarke, Rob M. A. Bie, Günther Deuschl, Karla Eggert, Jean-Luc Houeto, Jaime Kulisevsky, Dag Nyholm, Per Odin, Karen Østergaard, Werner Poewe, Pierre Pollak, Jose Martin Rabey, Olivier Rascol, Evzen Ruzicka, Michael Samuel, Hans Speelman, Olof Sydow, Francesc Valldeoriola, Chris Linden, Wolfgang Oertel, Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review, Journal of Neurology, 2013, 260, 11, 2701

    CrossRef

  52. 52
    Antonia Maass, Heinz Reichmann, Sleep and non-motor symptoms in Parkinson’s disease, Journal of Neural Transmission, 2013, 120, 4, 565

    CrossRef

  53. 53
    M. Zibetti, M. Rizzone, A. Merola, S. Angrisano, L. Rizzi, E. Montanaro, A. Cicolin, L. Lopiano, Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease, Acta Neurologica Scandinavica, 2013, 127, 5
  54. 54
    Giovanni Defazio, Angelo Gigante, Paola Mancino, Michele Tinazzi, The epidemiology of pain in Parkinson’s disease, Journal of Neural Transmission, 2013, 120, 4, 583

    CrossRef

  55. 55
    C. Ossig, H. Reichmann, Treatment of Parkinson’s disease in the advanced stage, Journal of Neural Transmission, 2013, 120, 4, 523

    CrossRef

  56. 56
    David Salat, Eduardo Tolosa, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  57. 57
    David Salat, Eduardo Tolosa, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  58. 58
    Francesca Del Sorbo, Alberto Albanese, Clinical management of pain and fatigue in Parkinson's disease, Parkinsonism & Related Disorders, 2012, 18, S233

    CrossRef

  59. 59
    Anders Johansson, Dag Nyholm, Continuous delivery of energy or L-dopa: Identifying advantages and limitations of DBS and levodopa–carbidopa intestinal gel in the absence of head-to-head comparisons, Basal Ganglia, 2012, 2, 4, 221

    CrossRef

  60. 60
    D. Santos-García, M. J. Añón, L. Fuster-Sanjurjo, R. de la Fuente-Fernández, Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson’s disease leads to improvement in caregivers’ stress and burden, European Journal of Neurology, 2012, 19, 9
  61. 61
    Dag Nyholm, Duodopa® treatment for advanced Parkinson's disease: A review of efficacy and safety, Parkinsonism & Related Disorders, 2012, 18, 8, 916

    CrossRef

  62. 62
    V. Pursiainen, J. Lyytinen, E. Pekkonen, Effect of duodenal levodopa infusion on blood pressure and sweating, Acta Neurologica Scandinavica, 2012, 126, 4
  63. 63
    Santiago Perez-Lloret, María Verónica Rey, Estelle Dellapina, Jean Pellaprat, Christine Brefel-Courbon, Olivier Rascol, Emerging analgesic drugs for Parkinson's disease, Expert Opinion on Emerging Drugs, 2012, 17, 2, 157

    CrossRef

  64. 64
    Pablo Martinez-Martin, Cristian Falup Pecurariu, Per Odin, Jacobus J. Hilten, Angelo Antonini, Jose M. Rojo-Abuin, Vanderci Borges, Claudia Trenkwalder, Dag Aarsland, David J. Brooks, Kallol Ray Chaudhuri, Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease, Journal of Neurology, 2012, 259, 8, 1639

    CrossRef

  65. 65
    Prashanth Reddy, Pablo Martinez-Martin, Alexandra Rizos, Anne Martin, Guy C. Faye, Ian Forgacs, Per Odin, Angelo Antonini, K. Ray Chaudhuri, Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease, Clinical Neuropharmacology, 2012, 35, 5, 205

    CrossRef

  66. 66
    D. Nyholm, K. Klangemo, A. Johansson, Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson’s disease, European Journal of Neurology, 2012, 19, 8
  67. 67
    Karin Busk, Dag Nyholm, Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease, Parkinsonism & Related Disorders, 2012, 18, 8, 1000

    CrossRef

  68. 68
    D. Santos-García, L. F. Sanjurjo, M. Macías, M. Llaneza, P. Carpintero, R. de la Fuente-Fernández, Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being, Acta Neurologica Scandinavica, 2012, 125, 3
  69. 69
    Oscar Bernal-Pacheco, Natlada Limotai, Criscely L. Go, Hubert H. Fernandez, Nonmotor Manifestations in Parkinson Disease, The Neurologist, 2012, 18, 1, 1

    CrossRef

  70. 70
    Angelo Antonini, Paolo Barone, Roberto Marconi, Letterio Morgante, Salvatore Zappulla, Francesco Ernesto Pontieri, Silvia Ramat, Maria Gabriella Ceravolo, Giuseppe Meco, Giulio Cicarelli, Massimo Pederzoli, Michela Manfredi, Roberto Ceravolo, Marco Mucchiut, Giampiero Volpe, Giovanni Abbruzzese, Edo Bottacchi, Luigi Bartolomei, Giuseppe Ciacci, Antonino Cannas, Maria Giovanna Randisi, Alfredo Petrone, Mario Baratti, Vincenzo Toni, Giovanni Cossu, Paolo Del Dotto, Anna Rita Bentivoglio, Michele Abrignani, Rossana Scala, Franco Pennisi, Rocco Quatrale, Rosa Maria Gaglio, Alessandra Nicoletti, Michele Perini, Tania Avarello, Antonio Pisani, Augusto Scaglioni, Paolo Emilio Martinelli, Francesco Iemolo, Laura Ferigo, Pasqualino Simone, Paola Soliveri, Biagio Troianiello, Domenico Consoli, Alessandro Mauro, Leonardo Lopiano, Giuseppe Nastasi, Carlo Colosimo, The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life, Journal of Neurology, 2012, 259, 12, 2621

    CrossRef

  71. 71
    Julia Lowin, Annika Bergman, K. Ray Chaudhuri, Leslie J. Findley, Claudia Roeder, Mathias Schifflers, Eifiona Wood, Stephen Morris, A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK, Journal of Medical Economics, 2011, 14, 5, 584

    CrossRef

  72. 72
    Fabian Klostermann, Constanze Jugel, Frank Marzinzik, Benefit from jejunal levodopa in a patient with apomorphine pump, Journal of Neurology, 2011, 258, 2, 311

    CrossRef

  73. 73
    P. Jenner, A. C. McCreary, D. K. A. Scheller, Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression, Journal of Neural Transmission, 2011, 118, 12, 1691

    CrossRef

  74. 74
    Ariane Park, Mark Stacy, Dopamine-Induced Nonmotor Symptoms of Parkinson's Disease, Parkinson's Disease, 2011, 2011, 1

    CrossRef

  75. 75
    Robert A. Hauser, Future Treatments for Parkinson's Disease: Surfing the PD Pipeline, International Journal of Neuroscience, 2011, 121, S2, 53

    CrossRef

  76. 76
    R. Carron, V. Fraix, C. Maineri, E. Seigneuret, B. Piallat, P. Krack, P. Pollak, A. L. Benabid, Stéphan Chabardès, High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review, Journal of Neural Transmission, 2011, 118, 6, 915

    CrossRef

  77. 77
    H.H. Fernandez, P. Odin, Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease, Current Medical Research and Opinion, 2011, 27, 5, 907

    CrossRef

  78. 78
    Juan Carlos Martinez-Castrillo, Lydia Vela, Javier del Val, Araceli Alonso-Canovas, Nonmotor Disorders and Their Correlation With Dopamine, The Neurologist, 2011, 17, S9

    CrossRef

  79. 79
    K. Ray Chaudhuri, Per Odin, Angelo Antonini, Pablo Martinez-Martin, Parkinson’s disease: The non-motor issues, Parkinsonism & Related Disorders, 2011, 17, 10, 717

    CrossRef

  80. 80
    Claudia Trenkwalder, Bryan Kies, Monika Rudzinska, Jennifer Fine, Janos Nikl, Krystyna Honczarenko, Peter Dioszeghy, Dennis Hill, Tim Anderson, Vilho Myllyla, Jan Kassubek, Malcolm Steiger, Marco Zucconi, Eduardo Tolosa, Werner Poewe, Erwin Surmann, John Whitesides, Babak Boroojerdi, Kallol Ray Chaudhuri, the RECOVER Study Group, Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER), Movement Disorders, 2011, 26, 1
  81. 81
    Pablo Martinez-Martin, Carmen Rodriguez-Blazquez, Monica M. Kurtis, K. Ray Chaudhuri, The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease, Movement Disorders, 2011, 26, 3
  82. 82
    Anne Marthe Meppelink, Rickard Nyman, Teus van Laar, Martje Drent, Ted Prins, Klaus Leonhard Leenders, Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease, Movement Disorders, 2011, 26, 2
  83. 83
    Rüdiger Hilker, Angelo Antonini, Per Odin, What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?, Journal of Neural Transmission, 2011, 118, 6, 907

    CrossRef

  84. 84
    O.-B. Tysnes, B. Müller, J. P. Larsen, Are dysautonomic and sensory symptoms present in early Parkinson’s disease?, Acta Neurologica Scandinavica, 2010, 122,
  85. 85
    Angelo Antonini, Giulia Ursino, Daniela Calandrella, Laura Bernardi, Mauro Plebani, Continuous dopaminergic delivery in Parkinson’s disease, Journal of Neurology, 2010, 257, S2, 305

    CrossRef

  86. 86
    D. Santos-García, M. Macías, M. Llaneza, L. Fuster-Sanjurjo, A. Echarri-Piudo, S. Belmonte, S. Blanco, Experience with continuous levodopa enteral infusion (Duodopa®)in patients with advanced Parkinson's disease in a secondary level hospital, Neurología (English Edition), 2010, 25, 9, 536

    CrossRef

  87. 87
    D. Santos-García, M. Macías, M. LLaneza, L. Fuster-Sanjurjo, A. Echarri-Piudo, S. Belmonte, S. Blanco, Experiencia con la infusión continua de levodopa intraduodenal (Duodopa®) en pacientes con enfermedad de Parkinson avanzada en un hospital de segundo nivel asistencial, Neurología, 2010, 25, 9, 536

    CrossRef

  88. 88
    N. Pavese, V. Metta, S. K. Bose, K. R. Chaudhuri, D. J. Brooks, Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction, Brain, 2010, 133, 11, 3434

    CrossRef

  89. 89
    P. Barone, Neurotransmission in Parkinson’s disease: beyond dopamine, European Journal of Neurology, 2010, 17, 3
  90. 90
    Huijuan Li, Meifen Zhang, Ling Chen, June Zhang, Zhong Pei, Ailing Hu, Qing Wang, Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson's disease, Movement Disorders, 2010, 25, 16
  91. 91
    Kayhan A. Tayarani-Binazir, Michael J. Jackson, Sarah Rose, C. Warren Olanow, Peter Jenner, Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets, Movement Disorders, 2010, 25, 3
  92. 92
    Sara Varanese, Zoe Birnbaum, Roger Rossi, Alessandro Di Rocco, Treatment of Advanced Parkinson's Disease, Parkinson's Disease, 2010, 2010, 1

    CrossRef

  93. 93
    Patrik Brundin, Roger A. Barker, Malin Parmar, Recent Advances in Parkinson’S Disease - Translational and Clinical Research, 2010,

    CrossRef

  94. 94
    K. Ray Chaudhuri, Per Odin, Recent Advances in Parkinson’S Disease - Translational and Clinical Research, 2010,

    CrossRef

  95. 95
    Nancy L Diaz, Cheryl H Waters, Current strategies in the treatment of Parkinson’s disease and a personalized approach to management, Expert Review of Neurotherapeutics, 2009, 9, 12, 1781

    CrossRef

  96. 96
    Angelo Antonini, Per Odin, Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, S97

    CrossRef

  97. 97
    Giovanni Mostile, Joseph Jankovic, Treatment of dysautonomia associated with Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, S224

    CrossRef

  98. 98
    Emma Lane, Maria Sundberg, Jan Pruszak, Stem Cells and Parkinson's Disease, Reviews in Cell Biology and Molecular Medicine,